Acadia Pharmaceuticals Inc.

XNASHealth care

Last traded price · USD

$21.43

−0.20%Delayed · Pre-market

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 15:58 IST · A quote does not mean the product is available to trade on your account.

Day's open: —
Previous close: $21.47
Volume: 302
Day's high: —
Day's low: —

In brief

Acadia Pharmaceuticals Inc. is a health care company listed on Nasdaq, valued at about $3.69B.
Its shares closed at $21.47 on 4 Nov 2026, down 1.7% over the past year.
From India you can buy ACAD in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Acadia Pharmaceuticals Inc. (ACAD) shares from India?

Yes. Indian residents can invest in the US stock market under the Reserve Bank of India's Liberalised Remittance Scheme (LRS), which lets a resident individual remit up to USD 250,000 per financial year, across all permitted purposes combined. US-listed stocks and ETFs are a permitted investment under the LRS. You are solely responsible for ensuring your remittances comply with the LRS annual limit, the applicable Tax Collected at Source (TCS) rules, and all reporting requirements, including Schedule FA in your income-tax return.

Do I need the price of a whole ACAD share to invest?

Yes. You can buy fractional shares, which lets you invest a fixed rupee/dollar amount even in high-priced stocks. For example, if one share trades at USD 1,000 and you invest USD 100, you receive 0.1 of a share.

How much can I invest in US stocks in a year?

Under the LRS, an Indian resident can remit up to USD 250,000 per financial year (April to March) across all permitted purposes combined, from their own funds. This is a per-individual limit set by the RBI.

Can I trade ACAD options or futures?

No. Under RBI / FEMA rules, the LRS does not permit margin trading or speculative instruments such as futures, options, or other derivatives. Your US account is a cash account, not a derivatives and margin account.

Insights

Quotes run fifteen minutes behind.

Behind SPY and its sector fund XLV over 1 year
1 month: +8.8% (SPY −1.6%, XLV +13.5%). 3 months: −25.5% (SPY −0.4%, XLV +15.5%). 1 year: −1.7% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: ACAD, SPY and XLV · as of 4 Nov 2026
Below its 50- and 200-day averages
The 4 Nov 2026 close of $21.47 was 7.4% below its 50-day average ($23.20) and 9.0% below its 200-day average ($23.60). It has closed below the 200-day for 30 sessions, since 24 Sep 2026. The 50-day average crossed below the 200-day on 2 Nov 2026, 2 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
Volume 2.3× its 30-session average on 4 Nov 2026
4 Nov 2026 volume of 4.7M shares was 2.3× the average of the 30 sessions before it (2.0M), as the price rose 4.4%. SPY traded 1.5× its own average that session.
Daily volume against a 30-session baseline · as of 4 Nov 2026
25% of the way up its 52-week range
Closed at $21.47 on 4 Nov 2026: 30.7% below the 52-week high of $30.96 (19 Aug 2026) and 16.7% above the low of $18.39 (13 Oct 2026).
Daily price bars, split-adjusted · as of 4 Nov 2026
Short interest at 5.3% of shares outstanding
9.1M shares were sold short at the 15 Oct 2026 settlement, 5.3% of the 172.3M shares outstanding; covering them would take 4.6 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month+8.8%

6 months−0.0%

1 year−1.7%

5 years+7.2%

Newswire

About

Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise into making a difference for underserved neurological and rare disease communities around the world. It has two franchises in neurological and rare diseases. Its neurological disease franchise is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. FDA for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.

Website

Notable moves

May 16, 2025
+26.48%
December 13, 2023
+34.48%
June 21, 2022
−33.32%

Newswire

About

Website

Notable moves

May 16, 2025
+26.48%
December 13, 2023
+34.48%
June 21, 2022
−33.32%

Acadia Pharmaceuticals Inc.

XNASHealth care

Last traded price · USD

$21.43

−0.20%Delayed · Pre-market

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 15:58 IST · A quote does not mean the product is available to trade on your account.

Day's open: —
Previous close: $21.47
Volume: 302
Day's high: —
Day's low: —

In brief

Acadia Pharmaceuticals Inc. is a health care company listed on Nasdaq, valued at about $3.69B.
Its shares closed at $21.47 on 4 Nov 2026, down 1.7% over the past year.
From India you can buy ACAD in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Acadia Pharmaceuticals Inc. (ACAD) shares from India?

Do I need the price of a whole ACAD share to invest?

How much can I invest in US stocks in a year?

Can I trade ACAD options or futures?

Insights

Quotes run fifteen minutes behind.

Behind SPY and its sector fund XLV over 1 year
1 month: +8.8% (SPY −1.6%, XLV +13.5%). 3 months: −25.5% (SPY −0.4%, XLV +15.5%). 1 year: −1.7% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: ACAD, SPY and XLV · as of 4 Nov 2026
Below its 50- and 200-day averages
The 4 Nov 2026 close of $21.47 was 7.4% below its 50-day average ($23.20) and 9.0% below its 200-day average ($23.60). It has closed below the 200-day for 30 sessions, since 24 Sep 2026. The 50-day average crossed below the 200-day on 2 Nov 2026, 2 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
Volume 2.3× its 30-session average on 4 Nov 2026
4 Nov 2026 volume of 4.7M shares was 2.3× the average of the 30 sessions before it (2.0M), as the price rose 4.4%. SPY traded 1.5× its own average that session.
Daily volume against a 30-session baseline · as of 4 Nov 2026
25% of the way up its 52-week range
Closed at $21.47 on 4 Nov 2026: 30.7% below the 52-week high of $30.96 (19 Aug 2026) and 16.7% above the low of $18.39 (13 Oct 2026).
Daily price bars, split-adjusted · as of 4 Nov 2026
Short interest at 5.3% of shares outstanding
9.1M shares were sold short at the 15 Oct 2026 settlement, 5.3% of the 172.3M shares outstanding; covering them would take 4.6 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month+8.8%

6 months−0.0%

1 year−1.7%

5 years+7.2%

Newswire

About

Website

Notable moves

May 16, 2025
+26.48%
December 13, 2023
+34.48%
June 21, 2022
−33.32%

Newswire

About

Website

Notable moves

May 16, 2025
+26.48%
December 13, 2023
+34.48%
June 21, 2022
−33.32%

Acadia Pharmaceuticals Inc.

Acadia Pharmaceuticals Inc. in brief

Behind SPY and its sector fund XLV over 1 year

Below its 50- and 200-day averages

Volume 2.3× its 30-session average on 4 Nov 2026

25% of the way up its 52-week range

Short interest at 5.3% of shares outstanding

Acadia Pharmaceuticals Inc.

Acadia Pharmaceuticals Inc. in brief

Behind SPY and its sector fund XLV over 1 year

Below its 50- and 200-day averages

Volume 2.3× its 30-session average on 4 Nov 2026

25% of the way up its 52-week range

Short interest at 5.3% of shares outstanding